Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study.
暂无分享,去创建一个
Martin Dawes | M. Dawes | Martin N Aloise | J Sidney Ang | Pieter Cullis | Diana Dawes | Robert Fraser | Gideon Liknaitzky | Andrea Paterson | Paul Stanley | Adriana Suarez-Gonzalez | Hagit Katzov-Eckert | A. Suarez-Gonzalez | Andrea Paterson | J. Ang | Paul Stanley | M. N. Aloise | Hagit Katzov-Eckert | Pieter Cullis | Diana Dawes | Robert Fraser | Gideon Liknaitzky | Martin Dawes Mbbs | M. N. Md | J. S. A. MSc | Pieter Cullis MSc | PhD Diana Dawes | Robert Fraser MSc | Gideon Liknaitzky PhD | MBChB Mba | BScPharm RPh | Paul Stanley Mbbs | Adriana Suarez-Gonzalez MSc
[1] Evangelos Kontopantelis,et al. Examining variations in prescribing safety in UK general practice: cross sectional study using the Clinical Practice Research Datalink , 2015, BMJ : British Medical Journal.
[2] G. Ginsburg,et al. Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. , 2014, Pharmacogenomics.
[3] P. Canonico,et al. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. , 2014, Pharmacogenomics.
[4] Roger B. Davis,et al. Physicians' decisions to override computerized drug alerts in primary care. , 2003, Archives of internal medicine.
[5] W. Assendelft,et al. Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19 , 2011, European Journal of Clinical Pharmacology.
[6] Alessandra Marengoni,et al. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity , 2015, BMJ : British Medical Journal.
[7] E. Oren,et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.
[8] J. Saldivar,et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility , 2016, Pharmacogenomics and personalized medicine.
[9] R. Altman,et al. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. , 2015, Mayo Clinic proceedings.
[10] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.
[11] Joshua Borus,et al. Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.
[12] William E. Evans,et al. Pharmacogenomics in the clinic , 2015, Nature.
[13] Melissa A. Basford,et al. Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.
[14] S. Haga,et al. Comparison of delivery strategies for pharmacogenetic testing services , 2014, Pharmacogenetics and genomics.
[15] D. Brixner,et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy , 2016, Journal of medical economics.
[16] Deirdre Hennessy,et al. Prescription medication use by Canadians aged 6 to 79. , 2014, Health reports.
[17] D. Ashcroft,et al. Prevalence of Adverse Drug Events in Ambulatory Care: A Systematic Review , 2011, The Annals of pharmacotherapy.
[18] Marc Berg,et al. Overriding of drug safety alerts in computerized physician order entry. , 2006, Journal of the American Medical Informatics Association : JAMIA.
[19] T. Mamiya,et al. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. , 2014, Pharmacogenomics.
[20] Ira J. Kalet,et al. Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support , 2010, BMC Bioinformatics.
[21] Emily S. Patterson,et al. Comparing the Effectiveness of Alerts and Dynamically Annotated Visualizations (DAVs) in Improving Clinical Decision Making , 2015, Hum. Factors.
[22] H. Britt,et al. BEACH program update. , 2015, Australian family physician.
[23] Thomas H. Payne,et al. Review Paper: Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A Review , 2007, J. Am. Medical Informatics Assoc..
[24] B. Franklin,et al. The causes of prescribing errors in English general practices: a qualitative study. , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.
[25] M. Lee,et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.
[26] A. Melander,et al. Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care , 2007, The Annals of pharmacotherapy.
[27] W. Ungar,et al. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada. , 2015, Genome.
[28] M. Relling,et al. Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.
[29] T. Skaar,et al. Implementation of a pharmacogenomics consult service to support the INGENIOUS trial , 2016, Clinical pharmacology and therapeutics.
[30] D. Bates,et al. Ambulatory Computerized Prescribing and Preventable Adverse Drug Events , 2016, Journal of patient safety.
[31] Russ B. Altman,et al. Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.
[32] C. Teljeur,et al. Prescriber variation in potentially inappropriate prescribing in older populations in Ireland , 2014, BMC Family Practice.
[33] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.